Announcements
- Celyad Oncology announces the termination of its American Depository Receipt program
- Publication of a rectified transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
- Publication of a transparency notification received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)
- Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
- Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
- Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights
- Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
More ▼
Key statistics
On Friday, Celyad Oncology SA (1C0:DEU) closed at 0.285, 14.46% above the 52 week low of 0.249 set on May 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.273 |
---|---|
High | 0.329 |
Low | 0.266 |
Bid | 0.1356 |
Offer | 0.464 |
Previous close | 0.278 |
Average volume | 20.00 |
---|---|
Shares outstanding | 41.43m |
Free float | 38.27m |
P/E (TTM) | -- |
Market cap | 12.59m EUR |
EPS (TTM) | -0.3287 EUR |
Data delayed at least 15 minutes, as of May 31 2024.
More ▼